Background: Warfarin is widely used as a treatment of venous thromboembolism and its capability to reduce the hazard of thromboembolic events has been unequivocally demonstrated. Variability between individuals, as well as a narrow therapeutic range are barriers to safe and effective warfarin therapy. Inadequate dose individualization contributes to under-utilization, 18-55% of patients who would benefit […]
Tag Archives | 2018
Total and unbound mycophenolic acid pharmacokinetics before and after kidney transplantation
January 24, 2018
Authors David Metz (1), Nick Holford (2), Noel Cranswick (1), John Kanellis (3), Peter Trnka (4), Amanda Walker (1), Frank Ierino (1)
Affiliations 1 University of Melbourne, 2 University of Auckland, 3 Monash University, 4 University of Queensland
Presentation type Oral
Presenters David Metz
Background: An increased incidence of acute rejection is seen with underexposure to mycophenolic acid (MPA) in the initial week post kidney transplantation, particularly in high immunological risk patients (1,2). Up to 25% of individuals in contemporary drug regimens are below the proposed therapeutic range at this time (3), and these individuals cannot be identified a […]
Study designs for renal drug studies
January 24, 2018
Authors Sudeep Pradhan (1), Daniel F.B. Wright (1), Stephen B. Duffull (1)
Affiliations 1. University of Otago
Presentation type Oral
Presenters Sudeep Pradhan
Introduction: Renal dose adjustment generally assumes a linear relationship between renal drug clearance and glomerular filtration rate (GFR). The theory underpinning this practice is the Intact Nephron Hypothesis (INH) [1], which assumes that nephrons are either completely functional (intact) or completely non-functional. There is a growing body of evidence to suggest that a non-linear relationship […]